PE20140425A1 - Derivados heterociclicos de amina - Google Patents
Derivados heterociclicos de aminaInfo
- Publication number
- PE20140425A1 PE20140425A1 PE2013002120A PE2013002120A PE20140425A1 PE 20140425 A1 PE20140425 A1 PE 20140425A1 PE 2013002120 A PE2013002120 A PE 2013002120A PE 2013002120 A PE2013002120 A PE 2013002120A PE 20140425 A1 PE20140425 A1 PE 20140425A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- amine
- halogen
- alkyl
- compounds
- Prior art date
Links
- -1 AMINE COMPOUNDS Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 102000011829 Trace amine associated receptor Human genes 0.000 abstract 1
- 108050002178 Trace amine associated receptor Proteins 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE AMINA DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C7), HALOGENO, ENTRE OTROS; m ES 1 O 2; Ar ES ARILO O HETEROARILO TAL COMO FENILO, NAFTILO, PIRIMIDINILO, PIRIDINILO, ENTRE OTROS; Y ES UN ENLACE, CH2, CH2CH2, CH(CF3), ENTRE OTROS; R2 ES H O ALQUILO(C1-C7); A ES CR O N, EN DONDE R ES H, CN, HALOGENO O ALQUILO(C1-C7); R' ES H O HALOGENO; B ES CH O N; n ES DE 0 A 2; X ES UN ENLACE, -CH2- U -O-. SON COMPUESTOS PREFERIDOS: (RS)-(4-CLORO-FENIL)-(4-MORFOLIN-2-IL-FENIL)-AMINA; ((S)-4-MORFOLIN-2-IL-FENIL)-NAFTALEN-2-IL-AMINA; (S)-4-CLORO-2-FLUOR-N-(4-(MORFOLIN-2-IL)FENIL)ANILINA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN AFINIDAD CON LOS RECEPTORES ASOCIADOS CON LAS AMINAS TRAZA (TAAR) SIENDO UTILES EN EL TRATAMIENTO DE DEPRESION, TRASTORNOS DE ANSIEDAD, ESQUIZOFRENIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11159566 | 2011-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140425A1 true PE20140425A1 (es) | 2014-03-28 |
Family
ID=45855803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002120A PE20140425A1 (es) | 2011-03-24 | 2012-03-21 | Derivados heterociclicos de amina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8802673B2 (es) |
| EP (1) | EP2688870B1 (es) |
| JP (1) | JP5716128B2 (es) |
| KR (1) | KR101518660B1 (es) |
| CN (1) | CN103443074B (es) |
| AR (1) | AR085478A1 (es) |
| AU (1) | AU2012230378B2 (es) |
| BR (1) | BR112013024312A2 (es) |
| CA (1) | CA2828283A1 (es) |
| CL (1) | CL2013002664A1 (es) |
| CO (1) | CO6801736A2 (es) |
| CR (1) | CR20130419A (es) |
| EA (1) | EA023237B1 (es) |
| EC (1) | ECSP13012896A (es) |
| IL (1) | IL228246A (es) |
| MA (1) | MA35062B1 (es) |
| MX (1) | MX351918B (es) |
| PE (1) | PE20140425A1 (es) |
| PH (1) | PH12013501905A1 (es) |
| SG (1) | SG193556A1 (es) |
| UA (1) | UA113167C2 (es) |
| WO (1) | WO2012126922A1 (es) |
| ZA (1) | ZA201306757B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101631003B1 (ko) | 2012-01-12 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체 |
| KR20150065190A (ko) * | 2012-11-07 | 2015-06-12 | 에프. 호프만-라 로슈 아게 | 피라진 유도체 |
| EP2928865B1 (en) | 2012-12-07 | 2018-04-11 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| MX2016007140A (es) * | 2013-12-11 | 2016-07-21 | Hoffmann La Roche | Proceso para la preparacion de 2-aril morfolinas quirales. |
| CA2946475A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP3137469B1 (en) | 2014-04-28 | 2019-10-09 | Pfizer Inc | Heterocyclic compounds and their use as dopamine d1 ligands |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| HRP20180933T1 (hr) * | 2014-05-28 | 2018-07-27 | F. Hoffmann - La Roche Ag | 5-oksa-2-azabiciklo[2.2.2]oktan-4-il i 5-oksa-2-azabiciklo[2.2.1]heptan-4-il derivati kao taar1 modulatori |
| WO2017192858A1 (en) * | 2016-05-04 | 2017-11-09 | Purdue Pharma L.P. | Oxazoline pseudodimers, pharmaceutical compositions and the use thereof |
| ES2926255T3 (es) | 2017-04-24 | 2022-10-24 | Tesaro Inc | Métodos de fabricación de niraparib |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| GB201809102D0 (en) * | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
| WO2020064792A1 (en) | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Heterocyclyl compounds for the treatment of autoimmune disease |
| JP6996029B2 (ja) * | 2018-09-30 | 2022-01-17 | エックスダブリューファルマ リミテッド | ニューロンヒスタミン受容体－３アンタゴニストとしての化合物およびその使用 |
| PH12022550188A1 (en) | 2019-07-24 | 2022-11-21 | Constellation Pharmaceuticals Inc | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| WO2022053541A1 (en) * | 2020-09-10 | 2022-03-17 | Eracal Therapeutics Ltd. | Compounds for use as appetite suppressant |
| AR129909A1 (es) | 2022-07-15 | 2024-10-09 | Hoffmann La Roche | Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
| WO2009016088A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
-
2012
- 2012-03-20 US US13/424,406 patent/US8802673B2/en active Active
- 2012-03-21 MX MX2013010954A patent/MX351918B/es active IP Right Grant
- 2012-03-21 MA MA36362A patent/MA35062B1/fr unknown
- 2012-03-21 AU AU2012230378A patent/AU2012230378B2/en not_active Ceased
- 2012-03-21 UA UAA201312080A patent/UA113167C2/uk unknown
- 2012-03-21 BR BR112013024312A patent/BR112013024312A2/pt not_active Application Discontinuation
- 2012-03-21 SG SG2013070776A patent/SG193556A1/en unknown
- 2012-03-21 CA CA2828283A patent/CA2828283A1/en not_active Abandoned
- 2012-03-21 PH PH1/2013/501905A patent/PH12013501905A1/en unknown
- 2012-03-21 PE PE2013002120A patent/PE20140425A1/es active IP Right Grant
- 2012-03-21 EP EP12709643.6A patent/EP2688870B1/en active Active
- 2012-03-21 EA EA201391341A patent/EA023237B1/ru not_active IP Right Cessation
- 2012-03-21 JP JP2014500358A patent/JP5716128B2/ja not_active Expired - Fee Related
- 2012-03-21 CN CN201280014644.5A patent/CN103443074B/zh not_active Expired - Fee Related
- 2012-03-21 KR KR1020137027851A patent/KR101518660B1/ko not_active Expired - Fee Related
- 2012-03-21 WO PCT/EP2012/054939 patent/WO2012126922A1/en not_active Ceased
- 2012-03-22 AR ARP120100939A patent/AR085478A1/es unknown
-
2013
- 2013-08-28 CR CR20130419A patent/CR20130419A/es unknown
- 2013-08-30 CO CO13206293A patent/CO6801736A2/es not_active Application Discontinuation
- 2013-09-02 IL IL228246A patent/IL228246A/en active IP Right Grant
- 2013-09-11 ZA ZA2013/06757A patent/ZA201306757B/en unknown
- 2013-09-16 CL CL2013002664A patent/CL2013002664A1/es unknown
- 2013-09-24 EC ECSP13012896 patent/ECSP13012896A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012230378B2 (en) | 2016-09-15 |
| EP2688870B1 (en) | 2017-02-01 |
| IL228246A (en) | 2017-10-31 |
| AU2012230378A1 (en) | 2013-09-12 |
| MX2013010954A (es) | 2013-10-07 |
| JP2014508790A (ja) | 2014-04-10 |
| CN103443074B (zh) | 2016-04-13 |
| KR20130132656A (ko) | 2013-12-04 |
| NZ616150A (en) | 2014-09-26 |
| ZA201306757B (en) | 2015-04-29 |
| EA201391341A1 (ru) | 2014-06-30 |
| BR112013024312A2 (pt) | 2016-07-19 |
| CL2013002664A1 (es) | 2014-05-09 |
| UA113167C2 (xx) | 2016-12-26 |
| JP5716128B2 (ja) | 2015-05-13 |
| ECSP13012896A (es) | 2013-11-29 |
| US20120245172A1 (en) | 2012-09-27 |
| HK1190703A1 (zh) | 2014-07-11 |
| EP2688870A1 (en) | 2014-01-29 |
| MX351918B (es) | 2017-11-03 |
| KR101518660B1 (ko) | 2015-05-07 |
| EA023237B1 (ru) | 2016-05-31 |
| WO2012126922A1 (en) | 2012-09-27 |
| CR20130419A (es) | 2013-10-09 |
| SG193556A1 (en) | 2013-11-29 |
| CO6801736A2 (es) | 2013-11-29 |
| CN103443074A (zh) | 2013-12-11 |
| MA35062B1 (fr) | 2014-04-03 |
| CA2828283A1 (en) | 2012-09-27 |
| US8802673B2 (en) | 2014-08-12 |
| PH12013501905A1 (en) | 2019-10-11 |
| AR085478A1 (es) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140425A1 (es) | Derivados heterociclicos de amina | |
| PE20081755A1 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| PE20080889A1 (es) | Aminometil-4-imidazoles | |
| PE20090896A1 (es) | Derivados de amidas como ligandos de los receptores taar1 | |
| PE20151538A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20091321A1 (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica | |
| BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| EA201391787A1 (ru) | Производные пиразола | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| PE20110398A1 (es) | BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA | |
| PE20141685A1 (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios | |
| AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
| PE20110405A1 (es) | Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion | |
| PE20110061A1 (es) | Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| PE20141380A1 (es) | Imidazopiridazinas como inhibidores de quinasa akt | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20141679A1 (es) | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |